Welcome to our dedicated page for INSPIRE VETERINARY PARTNER SEC filings (Ticker: IVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspire Veterinary Partners, Inc. (NASDAQ: IVP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and registration statements. These documents offer detailed insight into IVP’s veterinary hospital operations, financial condition, risk factors, and capital structure.
Through recent Form 8-K filings, Inspire has reported material events such as notices from the Nasdaq Stock Market regarding minimum bid price compliance, the scheduling of a Nasdaq hearings panel review, changes in its independent registered public accounting firm, the issuance of senior convertible promissory notes, and equity issuances related to consulting agreements and debt cancellation. These filings explain key terms of financing arrangements, conversion features, and potential dilution, and they describe events of default and use of proceeds.
The company’s S-1 registration statements describe its business model as an owner and operator of veterinary hospitals across the United States, outline services offered at its clinics, and provide extensive risk factor disclosures covering profitability, acquisition strategy, regulatory exposure, internal controls, and listing considerations. Proxy materials on Schedule 14A detail matters submitted to stockholders, such as director elections and auditor ratification, and explain voting rights associated with Class A and Class B common stock.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand issues such as new debt or equity financings, changes in auditors, Nasdaq listing status, and governance matters. Users can review annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive financial statements and management discussion, and monitor 8-Ks for real-time updates on significant corporate events. Insider ownership and equity incentive information can be explored through proxy statements and related filings.
By using this page, investors and researchers can efficiently navigate Inspire Veterinary Partners’ SEC reporting history, compare successive filings, and see how the company’s financial and regulatory profile develops over time.
Inspire Veterinary Partners, Inc. (IVP) is filing an S-1 that describes a roll-up veterinary business model driven by acquisitions of individual hospitals and related real estate. For the six months ended June 30, 2025, the company reported $16.59M of revenue (flat year-over-year) and a net loss of $5.45M, and it sustained a net loss of $3.03M for the three months ended June 30, 2025. Management discloses substantial acquisitions completed since 2021 (multiple clinics with transaction values reported) and ongoing financing from notes, convertible instruments, a common stock purchase agreement and other debt.
The filing discloses notes payable of approximately $11.98M, elevated interest expense and non-cash charges that contributed to a going-concern statement: management says additional financing is required to continue operations for the next 12 months. The prospectus also notes a Nasdaq listing deficiency and potential dilution from a range of outstanding warrants, options and preferred conversions totaling material share counts.
Erinn Thomas-Mackey, a director of Inspire Veterinary Partners, Inc. (IVP), reported acquiring 1,447 shares of Class A common stock through the exercise of a stock option on 09/26/2024. The option had a listed exercise price of $17 and the transaction leaves Ms. Thomas-Mackey with 1,447 shares held directly. The Form 4 notes the reported share amounts were adjusted for a 25-for-1 reverse stock split effected by the issuer on 01/27/2025.
The filing also discloses that this Form 4 was submitted late due to an inadvertent administrative error and bears a signature date of 09/22/2025.
Inspire Veterinary Partners, Inc. (IVP) filed an S-1 registration statement describing an offering of Class A common stock and related resale registration rights with investor Seven Knots, LLC. The company discloses it has a limited operating history, is not profitable, and has generated U.S. net operating loss carryforwards that may be unusable if future taxable income does not materialize. IVP lists numerous operational and regulatory risks including challenges integrating acquisitions, recruiting and retaining veterinarians, cybersecurity and data risks, compliance with state and federal veterinary and controlled-substance laws, and Nasdaq listing deficiency notices. The prospectus summarizes outstanding and potentially issuable equity: 3,609,285 Class A shares outstanding as of September 16, 2025; multiple tranches of warrants, options and convertible preferred stock that together could materially increase diluted shares (examples include 7,593,000 shares from conversion of Series B preferred, 1,092,896+1,092,896 warrants at $1.83, and 9,450,000 shares reserved under the 2022 Equity Incentive Plan). The offering contemplates up to 35,000,000 Class A shares in this offering on a pro forma as-adjusted basis and describes conditions required for purchase agreement effectiveness.
Inspire Veterinary Partners, Inc. (IVP) director Phillip Balatsos submitted an initial Form 3 stating he does not beneficially own any securities of the issuer. The filing notes the Form 3 was submitted late due to an inadvertent administrative error. The disclosure lists the relevant event date as 10/09/2024 and indicates the form was filed by a single reporting person.
Inspire Veterinary Partners, Inc. reports that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), known as the stockholders’ equity requirement. Nasdaq notified the company on August 26, 2025 that, based on a filing made with the SEC on August 20, 2025, the company now meets the required level of stockholders’ equity for continued listing on the Nasdaq Capital Market. The company later issued a press release on September 2, 2025 to publicly announce that it is once again in compliance with this Nasdaq listing standard.
Alexandra Quarti, identified as Vice President of Medical Operations, filed an initial Form 3 reporting her relationship to Inspire Veterinary Partners, Inc. (IVP) and the event date of 08/20/2025. The form states she does not beneficially own any securities of the issuer. The filing lists her business address in Virginia Beach, VA, and confirms this is an individual filing by one reporting person.
Laura Elizabeth Johnson, Vice President of Operations and a director-level reporting person for Inspire Veterinary Partners, Inc. (IVP), filed an initial Form 3 reporting the event dated 08/20/2025. The filing lists the reporting persons name and business address and explicitly states no securities are beneficially owned. The form is signed and dated 08/22/2025.
Inspire Veterinary Partners, Inc. reported that Nasdaq previously notified the company on April 10, 2025 that its stockholders’ equity of
The company then entered into a Securities Purchase Agreement on July 28, 2025 for a private placement of up to 7,590 shares of Series B convertible preferred stock and accompanying warrants, with an aggregate offering amount of up to
As of this report, the company believes that, because of the first closing of the private placement, it has regained compliance with Nasdaq’s stockholders’ equity requirement. Nasdaq will continue to monitor compliance, and the company may be subject to delisting if a future periodic report does not show that it remains in compliance.
Armistice Capital, LLC and Steven Boyd report a 9.99% beneficial stake in Inspire Veterinary Partners, Inc. The Schedule 13G/A shows Armistice Capital (Delaware) and Steven Boyd (U.S.) collectively beneficially own 228,584 shares of Class A common stock (CUSIP G0360L134). The filing attributes shared voting and dispositive power over all 228,584 shares and reports no sole voting or dispositive power. The reporting parties say the shares are held in the ordinary course of business and not to influence control. The statement notes the Master Fund is the direct holder and Armistice Capital acts as investment manager.
Anne Murphy, identified as a director of Inspire Veterinary Partners, Inc. (ticker: IVP), reported a derivative security transaction on Form 4. The filing discloses an acquisition dated 09/26/2024 of a stock option (right to buy) covering 1,447 shares of Class A common stock with an exercise price of $17 per share. The options are shown as exercisable on 09/26/2024 and expiring on 09/26/2034, and the reported post-transaction beneficial ownership is 1,447 shares held directly.
The form notes that reported share counts have been adjusted for a 25-for-1 reverse stock split effected on 01/27/2025. The filing states it was submitted late due to an "inadvertent administrative error" and is signed by Anne Murphy with a signature date of 08/08/2025.